FDA's "Import For Export" Proposed Rule Criticized By HIMA, Abbott Labs
This article was originally published in The Gray Sheet
Executive SummaryFDA's interpretation of the term "component" in its "Import for Export" proposed rule is too broad and needs to be narrowed, the Health Industry Manufacturers Association and Abbott Laboratories contend in separate but similarly worded comments recently submitted to the agency.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.